Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Pb Multiple | -8.2x - -9.1x | -8.7x |
| Historical Pb Multiple | -13.9x - 31.5x | -6.8x |
| Fair Value | €13.45 - €14.86 | €14.15 |
| Upside | 0.5% - 11.1% | 5.8% |
| Benchmarks | - | Full Ticker |
| Teva Pharmaceutical Industries Limited | - | DB:TEV |
| Luye Pharma Group Ltd. | - | DB:LUP |
| Indivior PLC | - | DB:2IVB |
| Dr. Reddy's Laboratories Limited | - | DB:RDDA |
| AB Science S.A. | - | ENXTPA:AB |
| MedinCell S.A. | - | ENXTPA:MEDCL |
| Select Price / Book Ratio | ||||||||
| Benchmark Companies | ||||||||
| TEV | LUP | 2IVB | RDDA | AB | MEDCL | |||
| DB:TEV | DB:LUP | DB:2IVB | DB:RDDA | ENXTPA:AB | ENXTPA:MEDCL | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | -16.4% | NM- | 24.3% | NM- | NM- | ||
| 3Y CAGR | NM- | -9.0% | NM- | 47.8% | NM- | NM- | ||
| Latest Twelve Months | -193.2% | -11.4% | -2500.0% | 2.8% | 64.2% | -19.0% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -10.5% | 8.7% | -0.5% | 14.2% | -1182.9% | -272.7% | ||
| Prior Fiscal Year | -3.5% | 10.1% | 0.2% | 18.3% | -1421.2% | -234.4% | ||
| Latest Fiscal Year | -9.9% | 8.7% | -4.0% | 19.9% | -1235.6% | -209.6% | ||
| Latest Twelve Months | -9.9% | 12.2% | -4.0% | 17.2% | -558.5% | -238.2% | ||
| Return on Equity | ||||||||
| 5 Year Average Margin | -16.3% | 5.4% | -15.5% | 16.1% | NA | -565.2% | ||
| Prior Fiscal Year | -7.3% | 4.7% | 3.9% | 21.4% | NM | NM | ||
| Latest Twelve Months | -25.5% | 3.5% | NA | 18.3% | NM | NM | ||
| Next Fiscal Year | 43.3% | 5.8% | -65.0% | 18.5% | 68.9% | 38.9% | ||
| Two Fiscal Years Forward | 31.6% | 6.3% | -71.0% | 16.3% | 40.8% | -3.9% | ||
| Current Trading Multiples | ||||||||
| Price / LTM Sales | 1.0x | 1.2x | 1.0x | 3.0x | 77.2x | 33.5x | ||
| Price / LTM EPS | -9.6x | 15.9x | -23.9x | 17.2x | -13.8x | -14.1x | ||
| Price / Book | 2.9x | 0.5x | -5.6x | 2.9x | -3.4x | -8.2x | ||
| Price / Fwd Book | 1.9x | 0.5x | -4.9x | 2.7x | -1.9x | -7.3x | ||
| Low | Mid | High | ||||||
| Benchmark P/B Ratio | -5.6x | 0.5x | 2.9x | |||||
| Historical P/B Ratio | -13.9x | -6.8x | 31.5x | |||||
| Selected P/B Multiple | -8.2x | -8.7x | -9.1x | |||||
| (x) Book Value | (54) | (54) | (54) | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | TEV | LUP | 2IVB | RDDA | AB | MEDCL | |
| Value of Common Equity | 16,260 | 7,503 | 1,162 | 882,113 | 83 | 442 | |
| (/) Shares Outstanding | 1,145.8 | 3,761.7 | 124.8 | 833.2 | 65.2 | 33.1 | |
| Implied Stock Price | 14.19 | 1.99 | 9.31 | 1,058.77 | 1.28 | 13.38 | |
| FX Conversion Rate to Trading Currency | 1.10 | 7.98 | 1.10 | 93.70 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 12.95 | 0.25 | 8.50 | 11.30 | 1.28 | 13.38 | |
| Trading Currency | EUR | EUR | EUR | EUR | EUR | EUR | |
| FX Rate to Reporting Currency | 1.10 | 7.98 | 1.10 | 93.70 | 1.00 | 1.00 | |